Latest Property Portfolio News

CVC Limited (ASX:CVC) ended FY26 with $87.7 million in cash after a major Laverton sale, debt refinancing and a decision to abandon a $124 million property settlement. The stronger liquidity position came alongside a 541.7% rise in underlying NPAT, although earnings remain dependent on lumpy property realisations and planning approvals.

AuMEGA Metals has uncovered a 100.5 g/t gold float sample at its Intersection Project in Newfoundland, the second-highest-grade sample recorded across its regional portfolio. Two further samples above 23 g/t strengthen the surface signal, although the results remain early-stage and most assays are still pending.

Energy Technologies has reported a deeper FY2026 loss, collapsing revenue and a $22.65 million equity deficiency, with its auditor flagging material uncertainty over the group’s ability to continue as a going concern. A five-year laser optics licence offers a potential new revenue path, but it remains conditional on development and future commercial sales.

Gowing Bros’ FY2026 loss widened to $3.49 million as Surf Hardware International remained deeply loss-making and investment properties were marked down by $3.0 million. The ASX-listed investment company kept its fully franked final dividend at 3 cents per share, despite negative operating cash flow and lower cash reserves.

Mayne Pharma has settled patent litigation with Sun Pharma over IMVEXXY, establishing 21 October 2032 as the agreed potential generic entry date, subject to court approval. The settlement involves no upfront payment, while one further Paragraph IV dispute remains unresolved.

Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.

Arena REIT delivered higher earnings, distributions and asset values in FY2026, but the failure of a major childcare tenant has forced a sharp reset in its near-term outlook. Edge Early Learning accounts for about 14% of rental income and is now in voluntary administration after missing rent.

Patrys has moved its injectable quetiapine program into human testing, while its FY2026 annual report warns the company will need further funding within 12 months. The company ended the year with $3.36 million in cash after raising capital and acquiring the RLS-2202 development program.

HomeCo Daily Needs REIT delivered stronger FY26 earnings, higher distributions and a 6% lift in portfolio value, supported by resilient leasing performance and property revaluations. The REIT expects funding costs to weigh on FY27 FFO even as it maintains its distribution guidance.

EVT delivered growth across hotels, cinemas and Thredbo in FY2026 while outlining an approximately $500 million non-core property divestment programme. The group is also reviewing its structure as it redirects capital towards asset-light hotel expansion and considers potential special dividends.

Abacus Group will sell its entire 19.60% interest in Storage King Group for $284.8 million, using the proceeds to repay debt and reduce gearing to about 30%. The transaction simplifies the group’s structure, but part of the sale still requires securityholder approval.

Dimerix has secured Mexican composition of matter protection for its Phase 2-ready kidney drug DMX-652 until June 2041. The grant expands the asset’s patent estate ahead of planned clinical testing in acute kidney injury, although it brings no new clinical data or regulatory approval.